United Therapeutics Insider Edgemond Files Form 4

TL;DR

**Insider Edgemond just filed a Form 4 for United Therapeutics, signaling a change in his holdings.**

AI Summary

This Form 4 filing, dated March 24, 2026, indicates that James Edgemond, an insider at United Therapeutics Corp, has filed a statement of changes in beneficial ownership of securities. While the filing itself doesn't detail specific transactions, it signals that Edgemond's holdings in United Therapeutics (ticker not explicitly stated but implied by the issuer) have changed. This matters to investors because insider activity can sometimes signal management's confidence (or lack thereof) in the company's future prospects, potentially influencing stock price movements.

Why It Matters

This filing alerts investors to a change in an insider's ownership, which can be a signal of their view on the company's future performance.

Risk Assessment

Risk Level: low — A Form 4 filing itself is a routine disclosure and doesn't inherently carry high risk, though the underlying transaction might.

Analyst Insight

A smart investor would look for the specific transaction details within the full Form 4 document to understand if Edgemond bought or sold shares, and then consider the size of the transaction relative to his total holdings to gauge its significance.

Key Players & Entities

• EDGEMOND JAMES (person) — Reporting Person
• UNITED THERAPEUTICS Corp (company) — Issuer of securities
• 0001636178 (person) — CIK of EDGEMOND JAMES
• 0001082554 (company) — CIK of UNITED THERAPEUTICS Corp

FAQ

Key Financial Figures

• $517.82 — multiple trades at prices ranging from $517.82 to $518.62. The price reported above re
• $518.62 — rades at prices ranging from $517.82 to $518.62. The price reported above reflects the
• $518.89 — multiple trades at prices ranging from $518.89 to $519.88. The price reported above re
• $519.88 — rades at prices ranging from $518.89 to $519.88. The price reported above reflects the
• $519.98 — multiple trades at prices ranging from $519.98 to $520.92. The price reported above re
• $520.92 — rades at prices ranging from $519.98 to $520.92. The price reported above reflects the
• $520.99 — multiple trades at prices ranging from $520.99 to $521.94. The price reported above re
• $521.94 — rades at prices ranging from $520.99 to $521.94. The price reported above reflects the
• $522.04 — multiple trades at prices ranging from $522.04 to $522.98. The price reported above re
• $522.98 — rades at prices ranging from $522.04 to $522.98. The price reported above reflects the
• $523.85 — multiple trades at prices ranging from $523.85 to $524.50. The price reported above re
• $524.50 — rades at prices ranging from $523.85 to $524.50. The price reported above reflects the
• $524.98 — multiple trades at prices ranging from $524.98 to $525.93. The price reported above re
• $525.93 — rades at prices ranging from $524.98 to $525.93. The price reported above reflects the
• $526.09 — multiple trades at prices ranging from $526.09 to $526.92. The price reported above re

Filing Documents

• primarydocument.html (4)
• primarydocument.xml (4) — 39KB
• 0001636178-26-000003.txt ( ) — 40KB

From the Filing

SEC FORM 4 SEC Form 4 FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10. 1. Name and Address of Reporting Person * EDGEMOND JAMES (Last) (First) (Middle) C/O UNITED THERAPEUTICS CORPORATION 1000 SPRING STREET (Street) SILVER SPRING MARYLAND 20910 (City) (State) (Zip) UNITED STATES (Country) 2. Issuer Name and Ticker or Trading Symbol UNITED THERAPEUTICS Corp [ UTHR ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) CFO AND TREASURER 2a. Foreign Trading Symbol 3. Date of Earliest Transaction (Month/Day/Year) 03/23/2026 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person 4. If Amendment, Date of Original Filed (Month/Day/Year) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 03/23/2026 M (1) 10,000 A $ 135.42 28,876 D Common Stock 03/23/2026 S (1) 200 D $ 518.283 (2) 28,676 D Common Stock 03/23/2026 S (1) 640 D $ 519.3025 (3) 28,036 D Common Stock 03/23/2026 S (1) 875 D $ 520.6164 (4) 27,161 D Common Stock 03/23/2026 S (1) 905 D $ 521.4662 (5) 26,256 D Common Stock 03/23/2026 S (1) 200 D $ 522.3645 (6) 26,056 D Common Stock 03/23/2026 S (1) 440 D $ 524.2001 (7) 25,616 D Common Stock 03/23/2026 S (1) 320 D $ 525.37 (8) 25,296 D Common Stock 03/23/2026 S (1) 520 D $ 526.5726 (9) 24,776 D Common Stock 03/23/2026 S (1) 80 D $ 527.4931 (10) 24,696 D Common Stock 03/23/2026 S (1) 2,620 D $ 529.043 (11) 22,076 D Common Stock 03/23/2026 S (1) 577 D $ 530.6366 (12) 21,499 D Common Stock 03/23/2026 S (1) 587 D $ 531.4904 (13) 20,912 D Common Stock 03/23/2026 S (1) 288 D $ 532.5947 (14) 20,624 D Common Stock 03/23/2026 S (1) 642 D $ 533.5959 (15) 19,982 D Common Stock 03/23/2026 S (1) 506 D $ 534.5972 (16) 19,476 D Common Stock 03/23/2026 S (1) 440 D $ 535.3358 (17) 19,036 D Common Stock 03/23/2026 S (1) 160 D $ 536.275 (18) 18,876 D Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Stock Option $ 135.42 03/23/2026 M 10,000 03/15/2023 03/15/2027 Common Stock 10,000 $ 0.00 152,500 D Explanation of Responses: 1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025. 2. This transaction was executed in multiple trades at prices ranging from $517.82 to $518.62. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. 3. This transaction was executed in multiple trades at prices ranging from $518.89 to $519.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a secur

View Full Filing

View this 4 filing on SEC EDGAR